Execution-focused CRO.
Predictable, high-quality trials.
Operational Excellence:
Gaea is built for execution. With over 40 years of hands-on healthcare and clinical research experience, our CEO/founder leads a lean, delivery- and quality-focused organisation, structured to avoid the inefficiencies of CROs.
We invest where it matters:
- Validated systems (Veeva Vault, MedNet)
- Robust computer system validation and provider qualification
- GDPR-compliant processes from dedicated QAM and Data Protection Officer
- Enterprise-grade cybersecurity delivered by a leading Estonian IT partner
We place particular emphasis on rigorous site feasibility and early operational planning—reducing delays, avoiding recruitment shortfalls, and improving predictability.
Our senior, locally embedded CRAs work closely with site teams to ensure enrolment, protocol adherence, and data quality.
Clinical operations and internal data management are fully integrated, ensuring real-time oversight and high-quality outputs throughout the study lifecycle.
Therapeutic Experience:
We have experience across a broad range of indications, including the most complex (intensive care) and chronic diseases in areas such as skin, respiratory and neurology.
Rather than list past work, we engage directly with sponsors to demonstrate relevant experience for each programme. We welcome detailed scientific and operational discussions early in the feasibility phase.
Regulatory & Local Expertise:
We operate effectively within the EU Clinical Trials Regulation (CTR) and CTIS environment
Our experience spans EU/EEA/Balkan countries as well as key external regions: the United Kingdom, Ukraine, the United States and now New Zealand (faster and more cost effective than Australia).
We support sponsors in navigating regulatory complexity with a pragmatic, country-level approach that reduces approval timelines and minimises rework.
Cost Efficiency:
Gaea is designed to deliver high-quality clinical trials without unnecessary overhead.
- Lean structure—no layered bureaucracy
- Competitive, experienced staff
- Transparent, fully itemised budgets
- Flexible scope aligned to sponsor priorities
We enable sponsors to control costs without compromising delivery, quality, or regulatory compliance.
Services
Clinical Project Management
Clinical Project Management
Look moreEnabling Technologies
Enabling Technologies
Look moreSite Feasibility and Selection
Site Feasibility and Selection
Look moreSite Monitoring
Site Monitoring
Look moreClinical data management
Clinical data management
Look morePharmacovigilance
Pharmacovigilance
Look moreQuality Management and Compliance
Quality Management and Compliance
Look morePatient Expense Reimbursement
Patient Expense Reimbursement
Look moreData Protection as a Service
Data Protection as a Service
Look moreIndications
Indications
Look moreNigel Goodman
CEO at Gaea OÜ CRO
I am passionate to bring products for significant diseases with unmet needs through trials in a fast effective way to quickly answer the clinical questions. I don’t believe using the largest CROs is always the cost-effective solution. The largest CROs must run a lot of trials to cover their cost base, though they take even the smallest trial these are small change. By necessity, risk-based monitoring becomes standard, face to face support to site staff is much reduced. Trials at sites are run by people, busy people, also managing patients in routine care.
In addition, my view is companies should all give back to the only world we live in – I choose to give back to sustainability here in Estonia, and education and conservation in Kenya.
Ukrainian patients need clinical research access more even than before and with the incredible engagement of research teams, we can perform clinical trials with fast patient recruitment, and minimum drop-out rates. To help us: on 22nd March 2023 the UA Competent Authority reduced an expert evaluation of a clinical trial application from 47 working days to 30 calendar days and shortened the approval timeline from 5 working days to 5 calendar days, a very significant reduction in time to launch your trial in Ukraine. (MoH order No 190 of 31st of January 2023).
